Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Petra J. Woestenberg*, Audrey J. King, Birgit H.B. Van Benthem, Suzan Leussink, Marianne A.B. Van Der Sande, Christian J.P.A. Hoebe, Johannes A. Bogaards

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman p = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.

Original languageEnglish
Pages (from-to)1280-1285
Number of pages6
JournalJournal of Infectious Diseases
Issue number8
Publication statusPublished - 2020

Cite this